Cytokine_NP Gene_NP Expression_NP by_IN Peripheral_NP Blood_NP Leukocytes_NP in_IN Horses_NP Experimentally_NP Infected_NP with_IN Anaplasma_NP phagocytophila_NP Human_NP granulocytic_JJ ehrlichiosis_NN (_( HGE_NP )_) ,_, a_DT tick-borne_JJ zoonosis_NN ,_, is_VBZ caused_VBN by_IN an_DT obligatory_JJ intragranulocytic_JJ bacterium_NN ,_, the_DT HGE_NP agent_NN ,_, a_DT strain_NN of_IN Anaplasma_NP phagocytophila_NN ._SENT The_DT equine_JJ model_NN of_IN HGE_NP is_VBZ considered_VBN valuable_JJ in_IN understanding_VBG pathogenic_JJ and_CC immune_JJ mechanisms_NNS of_IN HGE_NP ._SENT In_IN the_DT present_JJ study_NN ,_, cytokine_NN mRNA_NN expression_NN by_IN peripheral_JJ blood_NN leukocytes_NNS (_( PBLs_NP )_) in_IN horses_NNS was_VBD examined_VBN during_IN the_DT course_NN of_IN infection_NN by_IN intravenous_JJ inoculation_NN of_IN A._NP phagocytophila_NN or_CC by_IN allowing_VBG feeding_NN by_IN infected_JJ ticks_NNS ._SENT The_DT p44_JJ genes_NNS encoding_VBG the_DT major_JJ outer_JJ membrane_NN protein_NN P44s_NP of_IN A._NP phagocytophila_NN were_VBD detected_VBN by_IN PCR_NP in_IN PBLs_NP of_IN all_DT four_CD horses_NNS from_IN 4_CD to_TO 20_CD days_NNS postexposure_NN ._SENT During_IN the_DT 20-day_JJ infection_NN period_NN ,_, interleukin-1beta_NP (_( IL-1beta_NP )_) and_CC tumor_NN necrosis_NN factor_NN alpha_NN (_( TNF-alpha_NP )_) mRNA_NN expression_NN was_VBD upregulated_VBN in_IN PBLs_NNS of_IN all_DT four_CD horses_NNS ,_, and_CC IL-8_NP mRNA_NP expression_NN was_VBD upregulated_VBN in_IN three_CD horses_NNS ._SENT Gamma_NN interferon_NN ,_, IL-10_NP ,_, and_CC IL-12_JJ p35_JJ mRNAs_NNS were_VBD weakly_RB expressed_VBN in_IN only_RB one_CD horse_NN each_DT ._SENT IL-2_NP ,_, IL-4_NN ,_, IL-6_NP ,_, and_CC IL-12_JJ p40_JJ mRNA_NN expression_NN ,_, however_RB ,_, could_MD not_RB be_VB detected_VBN in_IN the_DT PBLs_NNS of_IN any_DT of_IN the_DT four_CD horses_NNS ._SENT These_DT results_NNS suggest_VBP that_IN IL-1beta_NP ,_, TNF-alpha_NP ,_, and_CC IL-8_NP generation_NN during_IN A._NP phagocytophila_NN infection_NN has_VBZ a_DT primary_JJ role_NN in_IN HGE_NP pathogenesis_NN and_CC immunomodulation_NN ._SENT Human_JJ granulocytic_JJ ehrlichiosis_NN (_( HGE_NP )_) is_VBZ characterized_VBN by_IN fever_NN ,_, chills_NNS ,_, headache_NN ,_, myalgia_NN ,_, and_CC laboratory_NN findings_NNS including_VBG leukopenia_NN ,_, anemia_NN ,_, and_CC thrombocytopenia_NN ,_, as_RB well_RB as_IN elevated_JJ liver_NN enzyme_NN activities_NNS ._SENT Delayed_JJ treatment_NN ,_, misdiagnosis_NN ,_, and/or_CC the_DT presence_NN of_IN immunosuppression_NN may_MD lead_VB to_TO a_DT severe_JJ or_CC fatal_JJ outcome_NN ._SENT HGE_NP has_VBZ been_VBN increasingly_RB recognized_VBN in_IN the_DT United_NP States_NPS and_CC various_JJ parts_NNS of_IN Europe_NP ._SENT HGE_NP is_VBZ caused_VBN by_IN a_DT strain_NN of_IN Anaplasma_NP phagocytophila_NN (_( the_DT HGE_NP agent_NN )_) ,_, a_DT gram-negative_JJ obligatory_JJ intragranulocytic_JJ bacterium_NN ._SENT The_DT white-footed_JJ mouse_NN (_( Peromyscus_NP leucopus_NN )_) is_VBZ considered_VBN to_TO be_VB a_DT major_JJ wild-animal_JJ reservoir_NN of_IN A._NP phagocytophila_NN in_IN the_DT northeastern_JJ United_NP States_NPS ,_, and_CC Ixodes_NP spp._NP ticks_VBZ ,_, the_DT vector_NN of_IN Borrelia_NP burgdorferi_NP ,_, the_DT agent_NN of_IN Lyme_NP disease_NN ,_, are_VBP considered_VBN to_TO be_VB the_DT vector_NN ._SENT Strains_NNS of_IN A._NP phagocytophila_NNS have_VBP also_RB been_VBN known_VBN to_TO cause_VB tick-borne_JJ fever_NN in_IN ruminants_NNS in_IN Europe_NP and_CC to_TO cause_VB equine_JJ ehrlichiosis_NN in_IN the_DT United_NP States_NPS (_( it_PP has_VBZ hence_RB formerly_RB been_VBN called_VBN Ehrlichia_NP phagocytophila_NP and_CC Ehrlichia_NP equi_NP )_) ._SENT Pathogenesis_NN and_CC cellular_JJ immune_JJ responses_NNS of_IN HGE_NP are_VBP not_RB well_RB defined_VBN ._SENT The_DT presence_NN of_IN low_JJ levels_NNS of_IN A._NP phagocytophila_NN in_IN the_DT blood_NN of_IN patients_NNS in_IN the_DT acute_JJ stage_NN and_CC autopsied_JJ patients_NNS '_POS tissues_NNS and_CC the_DT nature_NN of_IN clinical_JJ signs_NNS and_CC laboratory_NN findings_NNS suggest_VBP the_DT involvement_NN of_IN proinflammatory_JJ cytokines_NNS and_CC chemokines_NNS in_IN the_DT pathogenesis_NN ._SENT In_IN vitro_NN ,_, we_PP found_VBD that_IN A._NP phagocytophila_NN strain_NN HZ_NP ,_, isolated_VBN from_IN an_DT acute-stage_JJ HGE_NP patient_NN ,_, induced_VBN rapid_JJ and_CC strong_JJ proinflammatory_JJ cytokine_NN (_( interleukin-1beta_NN [_SYM IL-1beta_NP ]_SYM ,_, tumor_NN necrosis_NN factor_NN alpha_NN [_SYM TNF-alpha_NP ]_SYM ,_, and_CC IL-6_NP )_) mRNA_NN expression_NN by_IN human_JJ peripheral_JJ blood_NN leukocytes_NNS (_( PBLs_NP )_) and_CC monocytes_NNS within_IN 2_CD h_NN and_CC protein_NN secretion_NN within_IN 24_CD h_NN ._SENT However_RB ,_, only_RB IL-1beta_NP is_VBZ upregulated_JJ in_IN neutrophils_NNS ,_, and_CC the_DT mRNA_NN of_IN these_DT three_CD cytokines_NNS is_VBZ not_RB upregulated_JJ in_IN HL-60_NP cells_NNS ._SENT Within_IN 2_CD h_NN of_IN incubation_NN with_IN A._NP phagocytophila_NP ,_, IL-8_NP ,_, IL-10_NP ,_, gamma_NN interferon_NN (_( IFN-gamma_NP )_) ,_, IL-2_NP ,_, and_CC transforming_VBG growth_NN factor_NN beta_NN mRNAs_NNS are_VBP not_RB consistently_RB upregulated_JJ in_IN human_JJ PBLs_NNS ,_, suggesting_VBG that_IN for_IN these_DT cytokines_NNS ,_, gene_NN expression_NN either_CC is_VBZ not_RB induced_VBN or_CC is_VBZ induced_VBN at_IN later_JJR time_NN points_NNS in_IN vitro_NN ._SENT Akkoyunlu_NP et_FW al._FW reported_JJ IL-8_JJ production_NN by_IN retinoic_JJ acid-treated_JJ HL-60_NP cells_NNS (_( human_JJ promyelocytic_JJ leukemia_NN cell_NN line_NN )_) after_IN 24_CD h_NN (_( negative_JJ at_IN 12_CD h_NN for_IN both_DT mRNA_NN and_CC protein_NN )_) and_CC by_IN human_JJ neutrophils_NNS 7_CD h_NN postincubation_NN with_IN A._NP phagocytophila_NN in_IN vitro_NN ._SENT That_DT report_NN also_RB indicated_VBD that_IN no_DT IL-1alpha_NP ,_, IL-1beta_NP ,_, or_CC TNF-alpha_NP is_VBZ detected_VBN in_IN the_DT culture_NN supernatant_JJ of_IN retinoic_JJ acid-treated_JJ and_CC nontreated_JJ HL-60_NP cells_NNS at_IN 6_CD days_NNS after_IN the_DT addition_NN of_IN A._NP phagocytophila_NN ._SENT Klein_NP et_FW al._FW reported_VBD that_IN in_IN infected_JJ dimethyl_NN sulfoxide-treated_JJ HL-60_NP cells_NNS or_CC human_JJ bone_NN marrow_NN cells_NNS ,_, IL-8_NP and_CC other_JJ chemokine_NN levels_NNS ,_, but_CC not_RB that_IN of_IN IL-1_NP ,_, IL-6_NP ,_, or_CC TNF-alpha_NP in_IN the_DT culture_NN medium_NN ,_, were_VBD significantly_RB elevated_VBN at_IN 48_CD h_NN postinfection_NN ._SENT IL-8_JJ levels_NNS are_VBP significantly_RB increased_VBN in_IN the_DT blood_NN of_IN HGE_NP patients_NNS ._SENT Dumler_NP et_FW al._FW reported_VBD that_IN IFN-gamma_NP and_CC IL-10_NP levels_NNS are_VBP elevated_VBN in_IN acute-phase_NN (_( median_JJ ,_, 4_CD days_NNS after_IN onset_NN )_) sera_NN compared_VBN with_IN convalescent_JJ (_( median_JJ ,_, 31_CD days_NNS after_IN onset_NN )_) sera_NN from_IN HGE_NP patients_NNS or_CC normal_JJ controls_NNS whereas_IN serum_NN IL-1beta_NP ,_, TNF-alpha_NP ,_, and_CC IL-4_NN levels_NNS are_VBP not_RB elevated_VBN ._SENT Using_VBG C3H_NP mice_NNS ,_, which_WDT do_VBP not_RB show_VB clinical_JJ signs_NNS and_CC spontaneously_RB clear_VB the_DT infection_NN by_IN 15_CD days_NNS after_IN intraperitoneal_JJ inoculation_NN of_IN A._NP phagocytophila_NP ,_, splenic_JJ IL-12_NP and_CC IFN-gamma_NP mRNA_NN and_CC serum_NN IFN-gamma_NN levels_NNS are_VBP significantly_RB elevated_VBN starting_VBG at_IN 2_CD days_NNS postinfection_NN ,_, although_IN the_DT clearance_NN of_IN A._NP phagocytophila_NN is_VBZ not_RB delayed_VBN in_IN IFN-gamma-/-_NP mice_NNS ._SENT Considering_VBG apparently_RB conflicting_JJ data_NNS in_IN vitro_NN using_VBG cell_NN lines_NNS ,_, bone_NN marrow_NN cells_NNS ,_, or_CC human_JJ PBLs_NNS which_WDT were_VBD assayed_VBN at_IN varied_JJ time_NN points_NNS of_IN incubation_NN or_CC in_IN vivo_RB using_VBG a_DT transient_JJ mouse_NN infection_NN model_NN or_CC patients_NNS '_POS sera_NN ,_, an_DT equine_JJ model_NN of_IN HGE_NP may_MD be_VB useful_JJ for_IN clarifying_VBG the_DT importance_NN of_IN these_DT cytokines_NNS in_IN HGE_NP ._SENT Several_JJ reports_NNS have_VBP suggested_VBN that_IN the_DT horse_NN serves_VBZ as_IN a_DT more_RBR useful_JJ infection_NN and_CC disease_NN model_NN of_IN HGE_NP than_IN the_DT mouse_NN ,_, since_IN A._NP phagocytophila_NN isolated_VBN from_IN patients_NNS induces_VBZ clinical_JJ signs_NNS in_IN horses_NNS similar_JJ to_TO those_DT of_IN HGE_NP and_CC equine_JJ ehrlichiosis_NN ._SENT However_RB ,_, cytokine_NN responses_NNS in_IN horses_NNS infected_VBN with_IN A._NP phagocytophila_NNS have_VBP not_RB been_VBN described_VBN so_RB far_RB ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP investigated_VBD cytokine_JJ mRNA_NN expression_NN by_IN PBLs_NNS in_IN horses_NNS following_VBG transmission_NN of_IN A._NP phagocytophila_NN by_IN intravenous_JJ inoculation_NN or_CC tick_NN bite_NN ._SENT A._NP phagocytophila_NP ._SENT |_SYM HZ_NP strain_NN A._NP phagocytophila_NN ,_, isolated_VBN from_IN an_DT HGE_NP patient_NN ,_, was_VBD propagated_VBN in_IN HL-60_NP cells_NNS as_IN previously_RB described_VBN ._SENT The_DT percentage_NN of_IN infected_JJ cells_NNS was_VBD determined_VBN by_IN Diff-Quik_NP (_( Baxter_NP Scientific_NP Products_NP ,_, Obetz_NP ,_, Ohio_NP )_) staining_VBG as_RB previously_RB described_VBN ._SENT Horse_NN infection_NN ._SENT |_SYM Four_CD horses_NNS purchased_VBN from_IN Ohio_NP horse_NN farms_NNS were_VBD kept_VBN in_IN vector-proof_JJ stalls_NNS in_IN the_DT Equine_NP Isolation_NP Unit_NP (_( College_NP of_IN Veterinary_NP Medicine_NP ,_, The_DT Ohio_NP State_NP University_NP )_) ._SENT All_DT horses_NNS were_VBD mixed_VBN breed_NN ._SENT Horse_NN 1_CD was_VBD a_DT 2-year-old_JJ male_NN (_( 380-kg_JJ body_NN weight_NN [_SYM BW_NP ]_SYM )_) ,_, horse_NN 2_CD was_VBD a_DT 5-year-old_JJ male_NN (_( 200-kg_NP BW_NP )_) ,_, horse_NN 3_CD was_VBD a_DT 5-year-old_JJ male_NN (_( 180-kg_NP BW_NP )_) ,_, and_CC horse_NN 4_CD was_VBD a_DT 3-year-old_JJ female_NN (_( 170-kg_NP BW_NP )_) ._SENT Prior_RB to_TO A._NP phagocytophila_NN infection_NN ,_, these_DT animals_NNS were_VBD confirmed_VBN as_IN seronegative_JJ and_CC PCR_NP negative_JJ for_IN A._NP phagocytophila_NN ._SENT Horses_NNS 1_CD and_CC 2_CD were_VBD intravenously_RB (_( i.v._NP )_) inoculated_VBD with_IN A._NP phagocytophila_NN of_IN high_JJ passage_NN (_( HP_NP ;_: i.e._FW ,_, more_JJR than_IN 50_CD passages_NNS in_IN HL-60_NP cells_NNS )_) and_CC low_JJ passage_NN (_( LP_NP ;_: i.e._FW ,_, fewer_JJR than_IN 10_CD passages_NNS )_) ,_, respectively_RB ,_, at_IN 107_CD infected_JJ HL-60_NP cells_NNS (_( approximately_RB 80_CD %_NN infected_JJ cells_NNS )_) in_IN 5_CD ml_NN of_IN RPMI_NP 1640_CD medium_NN ._SENT A_DT total_NN of_IN 100_CD and_CC a_DT total_NN of_IN 47_CD infected_JJ Ixodes_NP scapularis_NN adults_NNS were_VBD allowed_VBN to_TO feed_VB on_IN horses_NNS 3_CD and_CC 4_CD ,_, respectively_RB ._SENT As_IN nymphs_NNS ,_, these_DT ticks_NNS were_VBD acquisition_NN fed_VBN on_IN experimentally_RB infected_JJ DBA/2_NP mice_NNS ._SENT Uninfected_JJ nymphs_NNS were_VBD kindly_RB provided_VBN by_IN S._NP R._NP Telford_NP (_( Harvard_NP School_NP of_IN Public_NP Health_NP ,_, Boston_NP ,_, Mass._NP )_) ._SENT All_DT horses_NNS were_VBD euthanized_JJ at_IN 24_CD days_NNS postinoculation_NN (_( PI_NP )_) or_CC postattachment_NN (_( PA_NP )_) ._SENT The_DT use_NN of_IN horses_NNS for_IN this_DT study_NN has_VBZ been_VBN approved_VBN by_IN the_DT Ohio_NP State_NP University_NP Institutional_NP Animal_NP Care_NP and_CC Use_NP Committee_NP ._SENT Clinical_JJ evaluation_NN ,_, hematology_NN ,_, PBL_NP preparation_NN ,_, morula_NN examination_NN ,_, and_CC indirect_JJ fluorescent_JJ antibody_NN (_( IFA_NP )_) testing_NN ._SENT |_SYM Fever_NP ,_, depression_NN ,_, anorexia_NN ,_, diarrhea_NN ,_, leukopenia_NN ,_, laminitis_NN ,_, and_CC other_JJ clinical_JJ signs_NNS were_VBD monitored_VBN daily_RB for_IN 20_CD days_NNS ._SENT For_IN complete_JJ blood_NN cell_NN counts_NNS ,_, blood_NN samples_NNS were_VBD taken_VBN from_IN the_DT jugular_JJ veins_NNS of_IN horses_NNS prior_RB to_TO injection_NN or_CC tick_NN attachment_NN (_( day_NN 0_CD )_) and_CC every_DT 4_CD days_NNS until_IN 20_CD days_NNS PI_NP or_CC PA_NP ._SENT To_TO prepare_VB the_DT PBL_NP fraction_NN ,_, the_DT blood_NN samples_NNS ,_, which_WDT were_VBD collected_VBN in_IN acid_JJ citrate_NN dextrose_NN anticoagulant_JJ tubes_NNS ,_, were_VBD centrifuged_VBN at_IN 500_CD x_NN g_NN for_IN 5_CD min_NN ._SENT Erythrocytes_NNS in_IN the_DT pellet_NN were_VBD lysed_VBN in_IN sterile_JJ 0.83_CD %_NN NH4Cl_NN solution_NN for_IN 3_CD min_NN at_IN room_NN temperature_NN ._SENT Cells_NNS were_VBD washed_VBN twice_RB by_IN centrifugation_NN (_( 500_CD x_SYM g_NN for_IN 5_CD min_NN )_) in_IN phosphate-buffered_JJ saline_NN (_( 137_CD mM_NP NaCl_NP ,_, 10_CD mM_NP Na2HPO4_NP ,_, 2.7_CD mM_NP KCl_NP ,_, 1.8_CD mM_NP KH2PO4_NP [_SYM pH_NN 7.2_CD ]_SYM )_) ._SENT Viabilities_NNS of_IN PBLs_NP were_VBD >98_JJ %_NN ,_, as_RB assessed_VBN by_IN the_DT trypan_JJ blue_JJ dye_NN exclusion_NN test_NN ._SENT Intracytoplasmic_JJ microcolonies_NNS (_( morulae_NNS )_) of_IN A._NP phagocytophila_NN were_VBD examined_VBN in_IN PBLs_NNS by_IN using_VBG Diff-Quik_NP staining_VBG and_CC IFA_NP using_VBG monoclonal_NN antibody_NN (_( MAb_NP )_) 5C11_JJ ._SENT The_DT IFA_NP test_NN was_VBD performed_VBN as_IN previously_RB described_VBN ._SENT The_DT serum_NN antibody_NN titer_NN was_VBD expressed_VBN as_IN the_DT reciprocal_NN of_IN the_DT highest_JJS dilution_NN of_IN serum_NN that_WDT showed_VBD a_DT positive_JJ reaction_NN ._SENT Reverse_JJ transcription_NN (RT)-PCR_NN for_IN cytokine_NN genes_NNS ._SENT |_SYM Total_NP RNA_NP was_VBD extracted_VBN from_IN equine_JJ PBLs_NNS (_( 107_CD )_) by_IN TRIzol_NP reagent_NN (_( GIBCO-BRL_NP )_) and_CC resuspended_JJ in_IN 90_CD mul_NN of_IN diethyl_JJ pyrocarbonate-treated_JJ sterile_JJ water_NN ._SENT As_IN a_DT positive_JJ control_NN ,_, PBLs_NNS (_( 107_CD )_) of_IN uninfected_JJ healthy_JJ horses_NNS were_VBD stimulated_VBN with_IN either_DT concanavalin_NP A_NP (_( ConA_NP ;_: Sigma_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) (_( 10_CD mug/ml_NN )_) or_CC Escherichia_NP coli_NNS lipopolysaccharide_NN (_( LPS_NP )_) (_( 10_CD mug/ml_NN )_) in_IN RPMI_NP 1640_CD medium_NN at_IN 37C_JJ for_IN 4_CD h._NP Total_NP RNA_NP (_( 2_CD mug_NN )_) was_VBD reverse_RB transcribed_VBN in_IN a_DT 30-mul_JJ reaction_NN mixture_NN containing_VBG 1x_NP reaction_NN buffer_NN (_( 50_CD mM_NP Tris-HCl_NP [_SYM pH_NN 8.3_CD ]_SYM ,_, 75_CD mM_NP KCl_NP ,_, 3_CD mM_NP MgCl2_NP )_) ,_, 0.5_CD mM_NNS each_DT deoxynucleoside_NN triphosphate_NN (_( dNTP_NN )_) ,_, 1_CD U_NP of_IN RNase_NP inhibitor_NN (_( GIBCO-BRL_NP )_) ,_, 1.5_CD muM_NN oligo(dT)_NN primer_NN ,_, and_CC 10_CD U_NN of_IN Moloney_NP murine_JJ leukemia_NN virus_NN reverse_NN transcriptase_NN (_( GIBCO-BRL_NP )_) at_IN 42C_JJ for_IN 1_CD h._NNS The_DT reaction_NN was_VBD terminated_VBN by_IN heating_NN at_IN 94C_NN for_IN 5_CD min_NN ,_, and_CC the_DT cDNA_NN was_VBD used_VBN in_IN the_DT PCR_NP ._SENT The_DT cDNA_NN (_( 2_CD mul_NN )_) was_VBD amplified_VBN in_IN a_DT 50-mul_NP reaction_NN mixture_NN containing_VBG 1x_NP PCR_NP buffer_NN (_( 10_CD mM_NP Tris-HCl_NP [_SYM pH_NN 8.3_CD ]_SYM and_CC 50_CD mM_NP KCl_NP )_) ,_, 1.5_CD mM_NP MgCl2_NP ,_, 0.2_CD mM_NNS each_DT dNTP_NN ,_, and_CC 0.4_CD muM_NN (_( each_DT )_) 3_CD '_'' and_CC 5_CD '_'' primers_NNS (_( 0.5_CD muM_NN each_DT primer_NN for_IN equine_JJ IL-8_NP mRNA_NN )_) ._SENT The_DT primers_NNS used_VBN for_IN equine_JJ IL-1beta_NP ,_, IL-2_NP ,_, IL-4_NN ,_, IL-6_NP ,_, IL-10_NP ,_, IL-12_NP p35/40_NP ,_, TNF-alpha_NP ,_, IFN-gamma_NP ,_, and_CC beta-actin_NN mRNA_NN detection_NN were_VBD as_RB previously_RB described_VBN ._SENT Primer_JJR sequences_NNS for_IN equine_JJ IL-8_NP mRNA_NN expression_NN ,_, designed_VBD based_VBN on_IN the_DT equine_JJ cDNA_NN sequence_NN (_( GenBank_NP accession_NN number_NN )_) ,_, were_VBD kindly_RB provided_VBN by_IN S._NP Giguere_NP (_( Department_NP of_IN Large_NP Animal_NP Clinical_NP Sciences_NPS ,_, College_NP of_IN Veterinary_NP Medicine_NP ,_, University_NP of_IN Florida_NP )_) ._SENT The_DT sequences_NNS were_VBD as_RB follows_VBZ :_: sense_NN ,_, 5'-GACTTCCAAGCTGGCTGTTGC-3_NP '_POS ,_, and_CC antisense_NN ,_, 5'-GTCCTCTTTAGAAACGCCTGC-3_NP '_POS ._SENT To_TO reduce_VB nonspecific_JJ priming_NN ,_, all_DT PCRs_NN were_VBD performed_VBN by_IN the_DT hot-start_NN method_NN :_: Taq_NP DNA_NP polymerase_NN (_( 2_CD U/reaction_NN ;_: GIBCO-BRL_NP )_) was_VBD added_VBN after_IN incubation_NN of_IN the_DT mixture_NN at_IN 94C_NN for_IN 5_CD min_NN ._SENT PCR_NP was_VBD 25_CD cycles_NNS (_( 27_CD cycles_NNS for_IN equine_JJ IL-8_NN )_) ,_, consisting_VBG of_IN denaturation_NN at_IN 94C_NN for_IN 45_CD s_NNS ,_, annealing_VBG at_IN 60C_JJ (_( 62C_JJ for_IN IL-8_NP )_) for_IN 45_CD s_NNS ,_, and_CC extension_NN at_IN 72C_NP for_IN 2_CD min_NN ._SENT The_DT final_JJ extension_NN was_VBD for_IN 7_CD min_NN ._SENT These_DT conditions_NNS were_VBD within_IN the_DT linear_JJ range_NN for_IN PCR_NP ,_, as_RB determined_VBN previously_RB ._SENT PCR_NP products_NNS (_( 10_CD mul_NN each_DT )_) were_VBD electrophoresed_VBN in_IN 1.5_CD %_NN agarose_NN gel_NN containing_VBG ethidium_NN bromide_NN (_( final_JJ concentration_NN ,_, 0.5_CD mug/ml_NN )_) at_IN 95_CD V_CD for_IN 1_CD h_NN and_CC photographed_VBN under_IN UV_NP illumination_NN with_IN a_DT gel_NN video_NN system_NN (_( Gel_NP Print_NP 2000i_NP ;_: Biophotonics_NP Corporation_NP ,_, Ann_NP Arbor_NP ,_, Mich._NP )_) ._SENT DNA_NP size_NN markers_NNS (_( HaeIII_NP fragments_NNS of_IN phiX174_JJ replicative-form_NN [_SYM RF_NP ]_SYM DNA_NN ;_: GIBCO-BRL_NP )_) providing_VBG bands_NNS from_IN 1,353_CD to_TO 72_CD bp_NN were_VBD run_VBN in_IN parallel_NN ._SENT PCR_NP of_IN p44_JJ genes_NNS of_IN A._NP phagocytophila_NN ._SENT |_SYM To_TO detect_VB A._NP phagocytophila_NN DNA_NN in_IN equine_JJ PBLs_NNS ,_, nested_VBD PCR_NP ,_, based_VBN on_IN the_DT multigene_JJ family_NN p44_NN genes_NNS encoding_VBG immunodominant_JJ outer_JJ membrane_NN protein_NN P44s_NP ,_, was_VBD performed_VBN ._SENT The_DT two_CD primer_NN pairs_VBZ p3726_JJ (5'-GCTAAGGAATTAGCTTATGA-3')-p4257_JJ (_( 5'-AGAAGATCATAACAAGCATTG-3_JJ '_'' )_) and_CC p3761_JJ (5'-CTGCTCKGCCAARACCTC-3')-p4183_NN (_( 5'-CAATAGTYTTAGCTAGTAACC-3_NP '_POS )_) (_( K_NP =_SYM T+G_NP ;_: R_NP =_SYM A+G_NP ;_: Y_NP =_SYM C+T_NP [_SYM mixed_JJ bases_NNS ]_SYM )_) that_WDT are_VBP located_VBN in_IN conserved_VBN regions_NNS of_IN p44_JJ genes_NNS (_( Q._NP Lin_NP ,_, N._NP Zhi_NP ,_, H.-Y_NP ._SENT Kim_NP ,_, H._NP Horowitz_NP ,_, G._NP Wormser_NP ,_, and_CC Y._NP Rikihisa_NP ,_, 101st_NP Gen._NP Meet_NP ._SENT Am_NP ._SENT Soc._NP Microbiol_NP ._SENT ,_, abstr_NP ._SENT D-204_NP ,_, p._NN 319_CD ,_, 2001_CD )_) were_VBD used_VBN ._SENT The_DT first_JJ and_CC second_JJ PCR_NP product_NN sizes_NNS were_VBD 531_CD and_CC 422_CD bp_NN ,_, respectively_RB ._SENT The_DT first_JJ PCR_NP was_VBD performed_VBN with_IN 3_CD min_NN of_IN denaturation_NN at_IN 94C_NN followed_VBN by_IN 27_CD cycles_NNS consisting_VBG of_IN 1_CD min_NN each_DT of_IN denaturation_NN at_IN 94C_NN ,_, annealing_VBG at_IN 55C_NN ,_, and_CC extension_NN at_IN 72C_NP ._SENT In_IN the_DT first_JJ cycle_NN ,_, each_DT 50-mul_NP PCR_NP mixture_NN contained_VBD 2_CD mug_NN of_IN RNA_NP ,_, 5_CD mul_NN of_IN 10x_NP reaction_NN buffer_NN ,_, 0.2_CD mM_NNS each_DT dNTP_NN ,_, 1.5_CD mM_NP MgCl2_NP ,_, 1.25_CD U_NP of_IN Taq_NP polymerase_NN ,_, and_CC 25_CD pmol_NN of_IN each_DT primer_NN of_IN the_DT primer_JJR pair_NN p3726-p4257_JJ ._SENT The_DT second_JJ PCR_NP was_VBD performed_VBN the_DT same_JJ as_IN the_DT first_JJ PCR_NP ,_, except_IN that_WDT the_DT annealing_VBG temperature_NN was_VBD 52C_JJ ,_, 1_CD mul_NN of_IN the_DT first_JJ PCR_NP product_NN was_VBD used_VBN as_IN template_NN ,_, and_CC 10_CD pmol_NN of_IN each_DT primer_NN of_IN the_DT primer_JJR pair_NN p3761-p4183_NN was_VBD used_VBN ._SENT Clinical_JJ signs_NNS and_CC hematology_NN ._SENT |_SYM Horse_NP 1_CD ,_, which_WDT had_VBD been_VBN inoculated_VBN i.v._JJ with_IN HP_NP A._NP phagocytophila_NN ,_, developed_VBN fever_NN (_( body_NN temperature_NN >_SYM 38.9C_JJ ;_: normal_JJ range_NN ,_, 37.5_CD to_TO 38.6C_NP )_) during_IN days_NNS 5_CD to_TO 8_CD and_CC 15_CD to_TO 18_CD PI_NP and_CC thrombocytopenia_NP (_( <1.1_x 1:20_CD )_) were_VBD detected_VBN from_IN day_NN 8_CD and_CC day_NN 4_CD PI_NP ,_, respectively_RB ._SENT The_DT maximum_JJ IgG_NP titers_NNS of_IN the_DT 2_CD horses_NNS were_VBD 1:320_CD on_IN days_NNS 12_CD and_CC 16_CD PI_NP ,_, respectively_RB ._SENT The_DT IgG_NP titers_NNS in_IN horse_NN 3_CD ,_, which_WDT had_VBD been_VBN infected_VBN by_IN attaching_VBG infected_JJ ticks_NNS ,_, were_VBD less_JJR than_IN 1:20_CD throughout_IN 20_CD days_NNS ,_, and_CC horse_NN 4_CD showed_VBD a_DT peak_JJ IgG_NP titer_NN of_IN 1:160_CD on_IN day_NN 12_CD PA_NP ._SENT Equine_JJ cytokine_NN mRNA_NN expression_NN ._SENT |_SYM Expression_NN of_IN several_JJ equine_JJ mRNAs_NNS (_( IL-1beta_NP ,_, IL-2_NP ,_, IL-4_NN ,_, IL-6_NP ,_, IL-8_NP ,_, IL-10_NP ,_, IL-12_NP p35/40_NP ,_, TNF-alpha_NP ,_, IFN-gamma_NP ,_, and_CC beta-actin_NN )_) by_IN PBLs_NNS in_IN the_DT four_CD horses_NNS infected_VBN with_IN A._NP phagocytophila_NN by_IN i.v._JJ inoculation_NN or_CC by_IN attaching_VBG infected_JJ ticks_NNS was_VBD measured_VBN following_VBG the_DT time_NN course_NN of_IN infection_NN by_IN RT-PCR_NP at_IN a_DT linear_JJ range_NN of_IN 25_CD or_CC 27_CD PCR_NP cycles_NNS ._SENT Contamination_NN of_IN RNA_NP preparations_NNS with_IN the_DT genomic_JJ DNA_NN was_VBD negligible_JJ ,_, because_IN PCR_NP products_NNS from_IN "_`` minus-reverse_JJ transcriptase_NN "_'' negative_JJ controls_NNS were_VBD not_RB detected_VBN in_IN all_DT specimens_NNS ._SENT Constitutively_RB expressed_VBN beta-actin_NN mRNA_NN served_VBN as_IN a_DT control_NN for_IN the_DT amount_NN of_IN input_NN RNA_NP across_IN the_DT samples_NNS ._SENT As_IN positive_JJ controls_NNS ,_, ConA-_NP and/or_CC E._NP coli_NNS LPS-induced_NP IL-1beta_NP ,_, TNF-alpha_NP ,_, IL-6_NP ,_, IFN-gamma_NP ,_, IL-8_NP ,_, IL-2_NP ,_, IL-4_NN ,_, IL-12_NP p35_NP ,_, IL-12_JJ p40_NN ,_, and_CC IL-10_NP mRNAs_NNS were_VBD clearly_RB detectable_JJ in_IN uninfected_JJ equine_JJ PBLs_NNS ,_, using_VBG the_DT primers_NNS and_CC our_PP$ RT-PCR_NP conditions_NNS ._SENT For_IN horse_NN 1_CD only_RB ,_, the_DT results_NNS for_IN all_DT 10_CD cytokine_NN and_CC beta-actin_NN mRNAs_NNS examined_VBN are_VBP shown_VBN ,_, and_CC for_IN the_DT remaining_VBG horses_NNS ,_, the_DT results_NNS for_IN only_RB the_DT cytokines_NNS whose_WP$ mRNAs_NNS were_VBD expressed_VBN and_CC IL-8_NP and_CC beta-actin_NN mRNAs_NNS are_VBP shown_VBN ._SENT Regardless_RB of_IN method_NN of_IN inoculation_NN (_( i.e._FW ,_, intravenous_JJ inoculation_NN or_CC tick_NN transmission_NN )_) ,_, expression_NN of_IN IL-1beta_NP and_CC TNF-alpha_NP mRNAs_NNS was_VBD induced_VBN in_IN all_DT four_CD horses_NNS by_IN A._NP phagocytophila_NN infection_NN ._SENT IL-8_NP mRNA_NP expression_NN was_VBD detected_VBN in_IN horses_NNS 1_CD ,_, 2_CD ,_, and_CC 4_CD but_CC not_RB in_IN horse_NN 3_CD ._SENT IFN-gamma_NP mRNA_NP expression_NN was_VBD weakly_RB induced_VBN only_RB in_IN horse_NN 2_CD ._SENT A_DT weak_JJ IL-10_NP mRNA_NN expression_NN level_NN was_VBD also_RB detected_VBN in_IN horse_NN 1_CD ._SENT In_IN horse_NN 4_CD ,_, IL-12_JJ p35_NN mRNA_NN was_VBD weakly_RB detected_VBN ._SENT Expression_NN of_IN IL-2_NP ,_, IL-4_NN ,_, IL-6_NP ,_, and_CC IL-12_JJ p40_JJ mRNAs_NNS was_VBD not_RB detectable_JJ in_IN the_DT PBLs_NNS of_IN any_DT infected_JJ horses_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Microcolonies_NNS (_( morulae_NNS )_) of_IN A._NP phagocytophila_NN Microcolonies_NNS (_( morulae_NNS )_) of_IN A._NP phagocytophila_NP (_( black_JJ arrowheads_NNS )_) found_VBN in_IN peripheral_JJ blood_NN neutrophils_NNS from_IN HP_NP A._NP phagocytophila-infected_JJ horse_NN 1_CD by_IN using_VBG Diff-Quik_NP staining_VBG and_CC IFA_NP with_IN MAb_NP 5C11_NP (_( insert_NN ,_, white_JJ arrowhead_NN )_) ._SENT Magnification_NN ,_, x625_NN ._SENT FIG._NN 2_CD ._SENT |_SYM p44_JJ gene_NN detection_NN of_IN A._NP phagocytophila_NN p44_NN gene_NN detection_NN of_IN A._NP phagocytophila_NN in_IN the_DT PBLs_NNS ._SENT The_DT levels_NNS of_IN A._NP phagocytophila_NN in_IN PBLs_NNS in_IN horses_NNS infected_VBN by_IN i.v._JJ inoculation_NN and/or_CC by_IN attachment_NN of_IN infected_JJ ticks_NNS were_VBD examined_VBN by_IN PCR_NP using_VBG p44_JJ gene-specific_NN primers_NNS ._SENT Input_NN DNA_NN was_VBD normalized_VBN by_IN beta-actin_NP PCR_NP ._SENT The_DT PCR_NP products_NNS were_VBD resolved_VBN on_IN agarose_JJ gels_NNS containing_VBG ethidium_NN bromide_NN ._SENT M_NP ,_, DNA_NP size_NN markers_NNS (_( HaeIII_NP fragments_NNS of_IN phiX174_JJ RF_NP DNA_NP )_) ;_: N_NP ,_, no_DT template_NN ;_: P_NN ,_, positive-control_NN DNA_NN from_IN cell-cultured_JJ A._NP phagocytophila_NN HZ_NP ._SENT FIG._NN 3_CD ._SENT |_SYM IFA_NP titers_NNS ,_, showing_VBG development_NN of_IN IgG_NP antibodies_NNS against_IN A._NP phagocytophila_NP IFA_NP titers_NNS ,_, showing_VBG development_NN of_IN IgG_NP antibodies_NNS against_IN A._NP phagocytophila_NN in_IN the_DT four_CD horses_NNS infected_VBN by_IN intravenous_JJ inoculation_NN of_IN HP_NP or_CC LP_NP A._NP phagocytophila_NN or_CC by_IN attachment_NN of_IN HP_NP A._NP phagocytophila-infected_JJ ticks_NNS ._SENT FIG._NN 4_CD ._SENT |_SYM Induction_NN of_IN cytokine_NN mRNAs_NNS in_IN PBLs_NNS from_IN four_CD horses_NNS infected_VBN with_IN A._NP phagocytophila_NN Induction_NN of_IN cytokine_NN mRNAs_NNS in_IN PBLs_NNS from_IN four_CD horses_NNS infected_VBN with_IN A._NP phagocytophila_NN ._SENT Total_NP RNA_NP was_VBD extracted_VBN from_IN equine_JJ PBLs_NNS and_CC subjected_VBN to_TO RT-PCR_NP ._SENT The_DT amount_NN of_IN cDNAs_NNS was_VBD normalized_VBN against_IN beta-actin_NN mRNA_NN in_IN corresponding_JJ samples_NNS ._SENT M_NP ,_, DNA_NP size_NN markers_NNS (_( HaeIII_NP fragments_NNS of_IN phiX174_JJ RF_NP DNA_NP )_) ;_: N_NP ,_, no_DT template_NN ._SENT Uninfected_JJ horse_NN PBLs_NNS were_VBD stimulated_VBN with_IN ConA_NP (_( C_NP )_) or_CC E._NP coli_NNS LPS_NP (_( L_NP )_) for_IN 4_CD h_NN in_IN vitro_NN ._SENT The_DT results_NNS shown_VBN are_VBP representative_JJ of_IN more_JJR than_IN three_CD assays_NNS ._SENT In_IN our_PP$ equine_JJ model_NN of_IN HGE_NP ,_, only_RB IL-1beta_NP and_CC TNF-alpha_NP mRNAs_NNS were_VBD consistently_RB upregulated_JJ in_IN all_DT four_CD horses_NNS ,_, regardless_RB of_IN A._NP phagocytophila_NN cell_NN culture_NN passage_NN number_NN or_CC route_NN of_IN infection_NN ._SENT This_DT suggests_VBZ that_IN A._NP phagocytophila-induced_VBD mild_JJ fever_NN ,_, neutropenia_NN ,_, and_CC thrombocytopenia_NNS are_VBP mediated_VBN in_IN horses_NNS through_IN the_DT induction_NN of_IN these_DT two_CD major_JJ proinflammatory_JJ cytokines_NNS ,_, which_WDT are_VBP known_VBN to_TO cause_VB these_DT changes_NNS ._SENT In_IN our_PP$ previous_JJ study_NN ,_, A._NP phagocytophila_NN or_CC rP44_NN induced_VBN IL-1beta_NP ,_, TNF-alpha_NP ,_, and_CC IL-6_NP mRNAs_NNS within_IN 2_CD h_NN PI_NP and_CC induced_VBN protein_NN within_IN 24_CD h_NN PI_NP in_IN human_JJ PBLs_NNS in_IN vitro_NN in_IN a_DT dose-dependent_JJ manner_NN ._SENT However_RB ,_, IL-6_NP mRNA_NP expression_NN was_VBD not_RB detectable_JJ in_IN our_PP$ equine_JJ model_NN ._SENT The_DT lack_NN of_IN IL-6_NP mRNA_NP induction_NN by_IN PBLs_NNS in_IN infected_JJ horses_NNS may_MD be_VB due_JJ to_TO low_JJ numbers_NNS of_IN A._NP phagocytophila_NN in_IN the_DT blood_NN of_IN horses_NNS ,_, since_IN IL-6_NP mRNA_NP induction_NN in_IN vitro_NN requires_VBZ 10-fold_JJ higher_JJR levels_NNS of_IN A._NP phagocytophila_NN than_IN TNF-alpha_NP or_CC IL-1beta_NP mRNA_NP induction_NN does_VBZ ._SENT The_DT lack_NN of_IN IL-6_NP mRNA_NP induction_NN may_MD be_VB also_RB related_VBN to_TO the_DT relatively_RB mild_JJ nature_NN of_IN clinical_JJ signs_NNS of_IN our_PP$ horses_NNS ._SENT Coinfection_NN of_IN C3H_NP mice_NNS with_IN B._NP burgdorferi_NP and_CC A._NP phagocytophila_NN was_VBD reported_VBN to_TO increase_VB the_DT levels_NNS of_IN A._NP phagocytophila_NN and_CC elevate_VB IL-6_JJ levels_NNS in_IN the_DT sera_NN at_IN 2_CD weeks_NNS postinfection_NN beyond_IN those_DT of_IN infection_NN with_IN B._NP burgdorferi_NNS alone_RB ._SENT One_CD report_NN observed_VBD that_IN in_IN sera_NN of_IN acute-phase_NN patients_NNS ,_, the_DT levels_NNS of_IN IL-1beta_NP ,_, TNF-alpha_NP ,_, and_CC IL-6_NP are_VBP not_RB elevated_VBN ._SENT Since_RB ,_, unlike_IN those_DT of_IN experimentally_RB infected_JJ animals_NNS ,_, it_PP is_VBZ difficult_JJ to_TO preserve_VB these_DT rapid-turnover_NN cytokines_NNS in_IN the_DT specimens_NNS of_IN human_JJ patients_NNS ,_, it_PP is_VBZ premature_JJ to_TO dismiss_VB the_DT role_NN these_DT cytokines_NNS play_VBP in_IN HGE_NP pathogenesis_NN ._SENT Acute-phase_NP HGE_NP patient_NN sera_NN contain_VBP significantly_RB higher_JJR levels_NNS of_IN IFN-gamma_NP than_IN convalescent-phase_NN sera_NN ._SENT A._NP phagocytophila_NN can_MD transiently_RB establish_VB infection_NN in_IN C3H_NP mice_NNS without_IN any_DT clinical_JJ signs_NNS ,_, and_CC these_DT mice_NNS develop_VBP significant_JJ IFN-gamma_NP levels_NNS in_IN serum_NN during_IN days_NNS 2_CD to_TO 8_CD postintraperitoneal_NN inoculation_NN with_IN A._NP phagocytophila-containing_NN blood_NN from_IN infected_JJ SCID_NN mice_NNS ._SENT Although_IN in_IN IFN-gamma-/-_NN mice_NNS ,_, initial_JJ infection_NN levels_NNS with_IN A._NP phagocytophila_NNS are_VBP greater_JJR than_IN in_IN control_NN mice_NNS ,_, the_DT speed_NN of_IN clearance_NN of_IN A._NP phagocytophila_NN does_VBZ not_RB differ_VB ._SENT In_IN our_PP$ study_NN ,_, IFN-gamma_NP mRNA_NP expression_NN was_VBD seen_VBN only_RB in_IN one_CD horse_NN ._SENT This_DT finding_NN may_MD be_VB related_VBN to_TO the_DT lack_NN of_IN spontaneous_JJ clearance_NN of_IN A._NP phagocytophila_NN from_IN the_DT blood_NN of_IN all_DT horses_NNS at_IN even_RB 20_CD days_NNS PI_NP or_CC PA_NP ._SENT The_DT role_NN of_IN IFN-gamma_NP in_IN clearance_NN of_IN A._NP phagocytophila_NN remains_VBZ to_TO be_VB studied_VBN ._SENT In_IN the_DT present_JJ study_NN ,_, IL-8_NP mRNA_NP expression_NN was_VBD upregulated_VBN in_IN 3_CD horses_NNS ;_: however_RB ,_, horse_NN 3_CD had_VBD the_DT weakest_JJS cytokine_NN response_NN overall_NN and_CC did_VBD not_RB show_VB IL-8_JJ mRNA_NN expression_NN ._SENT Recently_RB ,_, Akkoyunlu_NP et_FW al._FW proposed_VBN that_IN IL-8_NP generated_VBD by_IN neutrophils_NNS in_IN response_NN to_TO A._NP phagocytophila_NN facilitates_VBZ the_DT infection_NN ._SENT Klein_NP et_FW al._FW reported_VBD that_IN in_IN dimethyl_JJ sulfoxide-treated_JJ infected_JJ HL-60_NP cells_NNS or_CC human_JJ bone_NN marrow_NN cells_NNS ,_, IL-8_NP and_CC other_JJ chemokine_NN levels_NNS ,_, but_CC not_RB that_IN of_IN IL-1_NP ,_, IL-6_NP ,_, or_CC TNF-alpha_NP in_IN the_DT culture_NN medium_NN ,_, were_VBD significantly_RB elevated_VBN at_IN 48_CD h_NN postinfection_NN ._SENT Since_IN findings_NNS ,_, including_VBG those_DT of_IN our_PP$ present_JJ horse_NN study_NN ,_, indicate_VBP that_IN IL-8_NP mRNA_NP is_VBZ not_RB upregulated_JJ at_IN early_JJ stages_NNS of_IN infection_NN in_IN vitro_NN and_CC in_IN vivo_RB ,_, IL-8_NP does_VBZ not_RB seem_VB to_TO be_VB critical_JJ for_IN the_DT initial_JJ establishment_NN of_IN infection_NN ._SENT Overall_JJ clinical_JJ signs_NNS for_IN our_PP$ horses_NNS ,_, which_WDT were_VBD inoculated_VBN with_IN a_DT strain_NN from_IN an_DT HGE_NP patient_NN in_IN the_DT state_NN of_IN New_NP York_NP ,_, were_VBD milder_JJR than_IN those_DT reported_VBN with_IN studies_NNS using_VBG the_DT BDS_NP or_CC Webster_NP strain_NN from_IN Wisconsin_NP but_CC rather_RB similar_JJ to_TO those_DT using_VBG inoculation_NN with_IN a_DT New_NP York_NP strain_NN as_RB reported_VBD by_IN Chang_NP et_FW al._FW ._SENT In_IN the_DT study_NN of_IN Pusterla_NP et_FW al._FW ,_, at_IN day_NN 16_CD after_IN i.v._JJ inoculation_NN and_CC at_IN day_NN 18_CD after_IN inoculation_NN by_IN tick_NN attachment_NN ,_, A._NP phagocytophila_NP Webster_NP and_CC BDS_NP strains_NNS became_VBD undetectable_JJ by_IN real-time_JJ quantitative_JJ PCR_NP assays_NNS ,_, based_VBN on_IN the_DT presence_NN of_IN the_DT 16S_JJ rRNA_NN gene_NN in_IN the_DT blood_NN of_IN horses_NNS ._SENT However_RB ,_, A._NP phagocytophila_NP HZ_NP strain_NN p44_NN genes_NNS were_VBD detected_VBN at_IN day_NN 20_CD of_IN infection_NN in_IN four_CD horses_NNS in_IN the_DT present_JJ study_NN ,_, suggesting_VBG that_IN A._NP phagocytophila_NP establishes_VBZ subclinical_JJ persistent_JJ infection_NN in_IN horses_NNS ,_, as_RB suggested_VBN by_IN Chang_NP et_FW al._FW ._SENT A_DT pioneering_VBG phylogenic_JJ study_NN ,_, comparing_VBG different_JJ A._NP phagocytophila_NN strains_NNS from_IN patients_NNS and_CC animals_NNS in_IN the_DT United_NP States_NPS and_CC Europe_NP by_IN using_VBG the_DT ank_JJ gene_NN as_IN a_DT marker_NN ,_, showed_VBD that_IN Wisconsin_NP strains_NNS are_VBP closer_JJR to_TO Ehrlichia_NP equi_NP (_( A._NP phagocytophila_NP ,_, horse_NN isolate_NN ,_, 99.18_CD to_TO 99.24_CD %_NN amino_NN acid_NN identity_NN )_) than_IN New_NP York_NP strains_NNS (_( 97.90_CD to_TO 97.92_CD %_NN amino_NN acid_NN identity_NN )_) ._SENT Thus_RB ,_, it_PP is_VBZ possible_JJ that_IN Wisconsin_NP strains_NNS are_VBP more_RBR pathogenic_JJ to_TO horses_NNS but_CC cleared_VBD more_JJR rapidly_RB than_IN New_NP York_NP strains_NNS ._SENT Disease_NN severity_NN in_IN horses_NNS inoculated_VBN i.v._NP with_IN A._NP phagocytophila_NN strain_NN Webster_NP was_VBD reported_VBN to_TO be_VB dependent_JJ on_IN A._NP phagocytophila_NN passage_NN numbers_NNS in_IN culture_NN ._SENT This_DT finding_NN appears_VBZ to_TO be_VB among_IN those_DT of_IN studies_NNS that_WDT are_VBP not_RB evident_JJ unless_IN larger_JJR number_NN of_IN animals_NNS are_VBP tested_VBN ,_, since_IN we_PP did_VBD not_RB observe_VB clear_JJ differences_NNS in_IN clinical_JJ manifestations_NNS between_IN horses_NNS infected_VBN with_IN HP_NP and_CC LP_NP A._NP phagocytophila_NP HZ_NP strains_NNS ._SENT Using_VBG a_DT real-time_JJ quantitative_JJ PCR_NP assay_NN ,_, Pusterla_NP et_FW al._FW reported_VBD 55-fold-lower_JJ initial_JJ ehrlichial_JJ load_NN in_IN PBLs_NNS from_IN tick-infected_NN horses_NNS than_IN in_IN those_DT from_IN horses_NNS inoculated_VBD i.v._JJ ._SENT In_IN the_DT same_JJ study_NN ,_, however_RB ,_, higher_JJR ehrlichial_JJ levels_NNS in_IN the_DT blood_NN of_IN horses_NNS infected_VBN by_IN tick_NN attachment_NN were_VBD observed_VBN at_IN 7_CD days_NNS PI_NP ._SENT According_VBG to_TO the_DT findings_NNS based_VBN on_IN the_DT use_NN of_IN PCR_NP with_IN p44_JJ genes_NNS ,_, our_PP$ study_NN appears_VBZ to_TO support_VB their_PP$ observation_NN with_IN respect_NN to_TO the_DT lower_JJR rate_NN of_IN increase_NN of_IN ehrlichial_JJ growth_NN with_IN tick_NN transmission_NN than_IN with_IN intravenous_JJ inoculation_NN ._SENT Pusterla_NP et_FW al._FW did_VBD not_RB see_VB significant_JJ difference_NN in_IN antibody_NN titer_NN at_IN day_NN 30_CD PI_NNS between_IN intravenous_JJ and_CC tick_NN transmission_NN ._SENT In_IN the_DT present_JJ study_NN ,_, antibody_NN responses_NNS were_VBD lower_JJR by_IN tick_NN attachment_NN than_IN by_IN intravenous_JJ inoculation_NN ._SENT More_JJR studies_NNS are_VBP needed_VBN to_TO learn_VB whether_IN tick_NN inoculation_NN modulates_VBZ host_NN immune_JJ response_NN to_TO facilitate_VB the_DT infection_NN ._SENT 